NASDAQ:ATNF

180 Life Sciences Stock Forecast, Price & News

$9.98
-0.06 (-0.60 %)
(As of 04/16/2021 04:00 PM ET)
Add
Compare
Today's Range
$9.56
Now: $9.98
$11.00
50-Day Range
$3.94
MA: $6.48
$11.98
52-Week Range
$1.90
Now: $9.98
$13.05
Volume1.43 million shs
Average Volume2.96 million shs
Market Capitalization$179.96 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.55
180 Life Sciences Corp. develops pharmaceuticals for chronic pain and inflammatory diseases. It operates as a clinical-stage biotechnology company focused on the development of novel drugs that fulfil unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University. The company was founded in 2016 and is headquartered in Menlo Park, CA.
180 Life Sciences logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ATNF
CUSIPN/A
CIKN/A
Phone(678) 570-6791
EmployeesN/A
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$1.12 per share

Profitability

Net Income$-90,000.00

Miscellaneous

Market Cap$179.96 million
Next Earnings DateN/A
OptionableNot Optionable

Headlines

What's Happening With ATNF Stock And CELC Stock?
April 13, 2021 |  benzinga.com
180 Life Science Rallies 18%: Technical Levels To Watch
March 26, 2021 |  finance.yahoo.com
180 Life Sciences Corp. Rings the Opening Bell
November 27, 2020 |  nasdaq.com
See More Headlines

MarketRank

Overall MarketRank

0.33 out of 5 stars

Medical Sector

1776th out of 2,024 stocks

Pharmaceutical Preparations Industry

713th out of 772 stocks

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
$9.98
-0.06 (-0.60 %)
(As of 04/16/2021 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ATNF News and Ratings via Email

Sign-up to receive the latest news and ratings for ATNF and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











180 Life Sciences (NASDAQ:ATNF) Frequently Asked Questions

What stocks does MarketBeat like better than 180 Life Sciences?

Wall Street analysts have given 180 Life Sciences a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but 180 Life Sciences wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Who are 180 Life Sciences' key executives?

180 Life Sciences' management team includes the following people:
  • Jim N. Woody, Chief Executive Officer
  • Lawrence Pemble, Chief Operating Officer
  • Ozan Pamir, Chief Financial Officer
  • Jagdeep Nanchahal, Chief Medical Officer
  • Jonathan B. Rothbard, Chief Scientific Officer

Who are some of 180 Life Sciences' key competitors?

What is 180 Life Sciences' stock symbol?

180 Life Sciences trades on the NASDAQ under the ticker symbol "ATNF."

How do I buy shares of 180 Life Sciences?

Shares of ATNF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is 180 Life Sciences' stock price today?

One share of ATNF stock can currently be purchased for approximately $9.98.

How much money does 180 Life Sciences make?

180 Life Sciences has a market capitalization of $179.96 million.

What is 180 Life Sciences' official website?

The official website for 180 Life Sciences is www.kblmerger.com.

Where are 180 Life Sciences' headquarters?

180 Life Sciences is headquartered at 30 PARK PLACE SUITE 45E, NEW YORK NY, 10007.

How can I contact 180 Life Sciences?

180 Life Sciences' mailing address is 30 PARK PLACE SUITE 45E, NEW YORK NY, 10007. The company can be reached via phone at (678) 570-6791 or via email at [email protected]


This page was last updated on 4/18/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.